All Posts Tagged With: "ACOR"
(RX) Pharma & Biotech Stock Review – Industry Outlook
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant...
29Jan2010 | vitalstocks | 0 comments | Continued(ACOR) Acorda Therapeutics’ Multiple Sclerosis Drug Gets FDA Clearance
Recently, Acorda Therapeutics Inc. (ACOR) announced that the U.S. Food and Drug Administration (FDA) has cleared its oral drug Ampyra (dalfampridine) which aims to improve walking speed in patients suffering from multiple sclerosis (MS). The company expects to launch the drug...
25Jan2010 | vitalstocks | 0 comments | Continued(BIIB) Biogen’s Tysabri is a Blockbuster!
Biogen Idec Inc. (BIIB) recently announced that its multiple sclerosis (MS) drug Tysabri achieved blockbuster status in 2009. Sales of the drug, which is approved for relapsing forms of MS in the US and for relapsing-remitting MS in the EU, achieved $1 billion in sales in 2009....
13Jan2010 | vitalstocks | 0 comments | Continued(FACT) Facet Biotech Rejects Biogen Idec Again
Facet Biotech Corp. (FACT) once again rejected Biogen Idec Inc.’s (BIIB) intention to acquire all the outstanding shares of Facet common stock stating that the revised offer is inadequate and not in the best interests of Facet Biotech’s stockholders. Earlier this month,...
11Dec2009 | vitalstocks | 0 comments | Continued(RX) Big Pharma and Biotech – Industry Outlook
The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between...
9Nov2009 | Shawn | 0 comments | Continued(ACOR) Acorda Therapeutics – Bull of the Day
Acorda Therapeutics (ACOR) is one of the more interesting biotechnology companies under our coverage. The company’s key pipeline drug, Fampridine-SR, is currently under U.S. FDA review, with a decision expected in late January 2010. Outside the U.S., Acorda has partnered...
8Nov2009 | vitalstocks | 0 comments | Continued(BIIB) Biogen Reports Higher Earnings
Today morning, Biogen Idec (BIIB) reported third quarter earnings per share of $1.12, beating the Zacks Consensus Estimate of $1.02. The company reported earnings of 98 cents in the year-ago period. Revenues increased 3% to $1.12 billion, with Tysabri being the primary growth...
20Oct2009 | vitalstocks | 0 comments | Continued(BIIB) Biogen Extends Hostile Bid For Facet Biotech Corporation
Biogen Idec Inc. (BIIB) extended its tender offer for the acquisition of all of the outstanding shares of Facet Biotech Corporation (FACT) to December 16, 2009. The offer was previously set to expire on October 19, 2009. As of October 15, 2009, about 28,336 shares of Facet Biotech...
20Oct2009 | vitalstocks | 0 comments | Continued(FACT) Facet Investors Urged to Deny Biogen Idec Tender Offer
In line with expectations, Facet Biotech Corporation’s (FACT) board of directors unanimously recommended that its stockholders should reject the unsolicited conditional tender offer from Biogen Idec Inc. (BIIB), which is seeking to acquire all the outstanding shares of Facet...
12Oct2009 | vitalstocks | 0 comments | Continued(BIIB) Biogen Launches Hostile Bid for Partner Facet Biotech
After being refused twice, Biogen Idec (BIIB) launched a hostile bid to acquire its development partner, Facet Biotech (FACT) for $14.50 per share, by taking its offer directly to Facet’s shareholders. Biogen also sent a letter to Facet’s Board stating that Facet’s cash...
24Sep2009 | vitalstocks | 0 comments | Continued